PS-002 Gene Therapy Tested in Adults With IgA Nephropathy
Tests PS-002, a gene therapy, in adults with a kidney disease called IgA nephropathy.
Plain-language title generated from the registry record
Registry title: PS-002 for the Treatment of IgA Nephropathy in Adults
Key facts
- Where
- Baltimore and Miami, United StatesSee the 2 sites
- Phase
- Phase 1/2
Where in United States
- The Johns Hopkins HospitalBaltimore, United StatesTaking people
- University of Miami HospitalMiami, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Purespring Therapeutics Limited
- Trial code
- NCT07182227EU 2025-523201-14-00
- Record updated
- 9 September 2026
- Original description
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment.Read full original descriptionShow less
A Phase 1/2 Multicenter, Open Label, Two-part Study (Single Ascending Dose [Part 1], and Dose Expansion [Part 2]) to Evaluate Safety, Tolerability and Efficacy of PS-002, a Gene Therapy for the Treatment of Adult Participants With Primary IgA Nephropathy
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy. This will be a first-in-human study and will include participants at high risk of disease progression despite receiving current standard-of-care treatment.
Participants will be monitored for up to one year after receiving PS-002 and invited to take part in a long-term follow-up study (total follow-up: 5 years).
Inclusion: Diagnosis of primary IgA nephropathy (IgAN) as evidenced by renal biopsy; A historic kidney biopsy performed within 36 months prior to screening with reported evidence of complement component 3 (C3) deposition. If the participant had a kidney biopsy performed over 36 months prior to Screening, a new kidney biopsy should be carried out during the Screening period. This biopsy must exhibit signs of ongoing complement system activity; Proteinuria assessed during screening as UPCR greater than or equal to 0.75 g/g (greater than or equal to 750 mg/g) OR total protein excretion greater than or equal to 1 g/24 h (greater than or equal to 1000 mg/24h) sampled from 24 h urine collection; eGFR calculated using the CKD-EPI formula greater than or equal to 30 mL/min/1.73m\^2; Sitting office systolic blood pressure equal to or less than 140 mmHg, diastolic blood pressure equal to or less than 90 mmHg; All participants must have been on best supportive care for IgAN, as per region-specific requirements defined in the protocol.
Exclusion: Having a major concurrent non-IgAN-related disease that, in the opinion of the investigator, prevents the assessment of IgAN; History of serious infection requiring parenteral antibiotics within the past 8 weeks prior to study drug administration; Exposed to a live or attenuated vaccine within the 6 weeks prior to study drug administration; Participants with a known sensitivity or intolerance to corticosteroid therapy; Prior treatment with PS-002 or any other gene therapy, or participation in any other investigational trial during this study; Participants treated with potentially hepatotoxic medications unless they have been monitored in accordance with the drug label and have received a stable dose since >90 days prior to dosing without clinically significant liver enzyme fluctuations; Note: Other protocol-defined inclusion/exclusion criteria may apply; Any secondary IgAN defined as associated with gastrointestinal and liver disorders (liver cirrhosis, celiac disease, Crohn's disease, ulcerative colitis), autoimmune disorders (dermatitis herpetiformis, psoriasis, seronegative arthritis, systemic lupus erythematosus, rheumatoid arthritis), malignancy (IgA myeloma, lymphoma, lung cancer, renal cell cancer, cutaneous T-cell lymphoma), respiratory disorders (bronchiolitis obliterans, idiopathic pulmonary fibrosis) etc; History of malignancy; or bone marrow or organ transplant; History of, or currently active primary or secondary immunodeficiency, including known history of human immunodeficiency virus infection, and other severe immunodeficiency blood disorders; Presence of other significant medical conditions that would create an unacceptable procedure or anesthesia risk; Known hypersensitivity to study drug ingredients; Positive serology for hepatitis B or C, i.e., positive hepatitis B surface antigen or hepatitis C ribonucleic acid (RNA) viral load positive; A participant has nephrotic syndrome, defined for this purpose as 24 h urine protein greater than 3.5g with concurrent hypoalbuminemia (serum albumin less than 3.0 g/dL [less than 30 g/L]); Participants previously treated with immunosuppressive/immunomodulatory agents such as, but not limited to, cyclophosphamide, infliximab, complement inhibitor, canakinumab, mycophenolate mofetil, mycophenolate sodium, cyclosporine, tacrolimus, everolimus, or systemic corticosteroids (exposure greater than 7.5mg/day prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to Screening. Participants previously or currently receiving oral budesonide (Kinpeygo/Tarpeyo) require wash out for 90 days prior to the study drug administration; Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the upper limit of normal.